IDL Biotech signs distributor agreement in Ghana
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.
May 2019
Information from the Annual General Meeting
The Annual General meeting was held on the 28th of May 2019.
Read the information here (in swedish).
IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.
IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.
